The Forum's two days of sessions addressed key issues in the critical path to TB drug registration, biomarkers for TB drug development, designing pivotal trials, conducting registration trials in high burden countries and developing regimens containing multiple novel agents.
These Open Forum meetings are designed to bring together regulators, TB drug developers and other interested stakeholders, such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high burden countries.
|
|
Thanks to a generous offer from the Kaiser Family Foundation, Open Forum 2 is available as a webcast on the Kaiser Family Foundation's website.
> click here to view the webcast
|
